StemExpress expands into clinical market

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

Aug 23, 2018
StemExpress

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of its Clinical Grade Non-Transfusable products to researchers and clinicians developing studies related to transplantation, cell therapy, regenerative medicine, investigational new drug development and medical devices in preclinical and clinical phases. These new Clinical Grade Non-Transfusable products support a smooth transition from laboratory prototype to commercial production.

The new product line features Clinical Grade Non-Transfusable Bone Marrow, Leukopaks®, Mobilized Leukopaks,® and Primary Cells. Soon to follow will be Transfusable Grade Clinical products. 

Currently, with intercontinental staff and four locations nationwide, StemExpress facilities follow and comply with strict CFR 1271 FDA guidelines regarding the production, processing, and management of tissue-based cellular products to ensure overall quality and compliance, which is paramount to the success of the researchers and clinicians StemExpress supports. Through IRB-approved collection processes and protocols and with an ISO certified cGMP compliant cell manufacturing facility, the new Clinical Grade Non-Transfusable products will support pharmaceutical, biotechnology, medical device, and academic institutions that are striving to develop therapies, cures, and answers to diseases that affect all people.